Merck to buy Aton Pharma
February 26, 2004
Business Wire reports that Merck & Co., Inc., one of the world''s leading research-based pharmaceutical companies, and Aton Pharma, Inc., a privately held biotechnology company focusing on the development of novel treatments for cancer and other serious diseases, have entered into a definitive agreement under which Merck will acquire Aton. Under the terms of the agreement, Merck will acquire 100 percent of the equity of Aton and Aton will become a wholly owned subsidiary of Merck. Aton, which was founded in 2001 and is located in Tarrytown, N.Y., has been focused on the identification and development of small molecule inhibitors of chromatin-modifying enzymes. The company''s clinical pipeline of histone deacetylase (HDAC) inhibitors represents a promising class of anti-tumor agents with a novel mechanism of action. Merck & Co., Inc. is a global research-driven pharmaceutical products company.